激肽释放酶原(PK)重组蛋白
Recombinant Prekallikrein (PK)
KLKB1; KLK3; Fletcher Factor; Kallikrein B,Plasma; Kininogenin; Plasma prekallikrein
- 编号RPB801Hu01
- 物种Homo sapiens (Human，人) 相同的名称，不同的物种。
- 来源原核表达
- 宿主E.coli
- 内毒素水平<1.0EU/µg(LAL法测定)
- 亚细胞定位分泌
- 预测分子量26.9kDa
- 实际分子量27kDa(差异分析请参阅说明书)
- 片段与标签Thr156~Thr364 with N-terminal His Tag
- 缓冲液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性状冻干粉
- 纯度> 95%
- 等电点8.2
-
应用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，请参见活性蛋白。 - 下载 英文说明书 中文说明书
- 规格 10µg50µg 200µg 1mg 5mg
- 价格 ¥ 1080 ¥ 2700 ¥ 5400 ¥ 16200 ¥ 40500
- 欲了解实际交易价格和更多情况，请与当地经销商联系!
-
产品包装(模拟)
-
产品包装(模拟)
-
SDS-PAGE图
-
通过ISO 9001、ISO 13485质量体系认证
序列
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
储存
避免反复冻融。2-8°C不超过一个月，-80°C不超过12个月。
稳定性
热稳定性以损失率显示。损失率是由加速降解试验决定，具体方法如下：在37°C孵育48小时，没有显著的降解或者沉淀产生。保质期内，在适当的条件下存储，损失率低于5%。
增值服务
相关产品
| 编号 | 适用物种：Homo sapiens (Human，人) | 应用(仅供研究使用，不用于临床诊断！) |
| RPB801Hu01 | 激肽释放酶原(PK)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAB801Hu01 | 激肽释放酶原(PK)多克隆抗体 | WB; IHC; ICC; IP. |
| MAB801Hu22 | 激肽释放酶原(PK)单克隆抗体 | WB; IHC; ICC; IP. |
| SEB801Hu | 激肽释放酶原(PK)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMB801Hu | 激肽释放酶原(PK)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
参考文献
| 杂志 | 参考文献 |
| Int J Immunopathol Pharmacol | Altered activities of kininase II, an angiotensin converting enzyme, prekallikrein, and nitric oxide in Kuwaiti patients with type 2 diabetes [PubMed: 25964383] |
| Thromb Res | Factor XII–mediated contact activation related to poor prognosis in disseminated intravascular coagulation [PubMed: 26706311] |
| Thrombosis Research | Factor XII-mediated contact activation related to poor prognosis in disseminated intravascular coaCavia (Guinea pig )lation [Pubmed:26706311] |
| Annals of Laboratory Medicine | The First Case of Congenital Prekallikrein Deficiency in Korea With a Novel Pathogenic Variant (c. 1198G> T) [Pubmed: 30430790] |
| J Cell Mol Med | Huaier shows anti©\cancer activities by inhibition of cell growth, migration and energy metabolism in lung cancer through PI3K/AKT/HIF©\1¦Á pathway [33377619] |
| J Thromb Thrombolysis | Contact system activation in disseminated intravascular coagulation: activities of prekallikrein and high-molecular-weight kininogen are significant risk factors [Pubmed:34993714] |
留言咨询